Relay Therapeutics Inc is a biotechnology business based in the US. Relay Therapeutics Inc shares (RLAY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.66 – a decrease of 19.79% over the previous week. Relay Therapeutics Inc employs 294 staff and has a trailing 12-month revenue of around $10 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.66 |
|---|---|
| 52-week range | $5.03 - $12.14 |
| 50-day moving average | $6.75 |
| 200-day moving average | $7.45 |
| Wall St. target price | $21.91 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.52 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.89 from 2024-11-18
| 1 week (2024-11-14) | -12.68% |
|---|---|
| 1 month (2024-10-21) | -23.95% |
| 3 months (2024-08-21) | -34.10% |
| 6 months (2024-05-21) | -35.32% |
| 1 year (2023-11-21) | -38.57% |
|---|---|
| 2 years (2022-11-21) | -73.77% |
| 3 years (2021-11-19) | 34.49 |
| 5 years (2019-11-17) | N/A |
| Revenue TTM | $10 million |
|---|---|
| Gross profit TTM | $1.4 million |
| Return on assets TTM | -26.87% |
| Return on equity TTM | -42.69% |
| Profit margin | 0% |
| Book value | $5.03 |
| Market Capitalization | $937.3 million |
TTM: trailing 12 months
We're not expecting Relay Therapeutics Inc to pay a dividend over the next 12 months.
Over the last 12 months, Relay Therapeutics Inc's shares have ranged in value from as little as $5.03 up to $12.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Relay Therapeutics Inc's is 1.675. This would suggest that Relay Therapeutics Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.